Literature DB >> 8732477

Investigation of the association of major histocompatibility complex genes, including HLA class I, class II and TAP genes, with clinical forms of Crohn's disease.

D Hesresbach1, M Alizadeh, J F Bretagne, A Gautier, F Quillivic, B Lemarchand, M Gosselin, B Genetet, G Semana.   

Abstract

The aim of this study was to determine immunogenetic markers of susceptibility in Crohn's disease (CD), taking the different features of the clinical course of the disease into account. HLA class I, HLA class II and TAP transporter gene polymorphisms were studied using DNA typing methods. Gene and antigen frequencies were analysed and compared in a group of 102 CD patients and 200 unrelated healthy controls from the same area. Analysis of the whole CD patient population revealed no definite association with either HLA or TAP gene alleles, with the exception of an association with DRB1*1302 (Pc < 0.05). However, when clinical subgroups of patients were considered, specific associations with some genetic markers were found. The most definitive results involved a genetic association in the group of patients who did not respond to glucocorticoid therapy. This group was characterized by a high frequency of HLA-DRB1*04 (P < 0.05). Conversely, a positive association with the TAP2-A allele was found in cortico-responder patients (Pc < 0.03). Furthermore, analysis of the distribution of HLA class II alleles in relation to the presence of extra-intestinal manifestations revealed an association with the DQB1*0501 or *0503 suballele of DQ5 (P < 0.05). Finally, patients with lesions in the small bowel were more frequently HLA DRB1*07 (P < 0.05). The present study supports the concept of clinical heterogeneity in Crohn's disease associated with a background of genetic heterogeneity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8732477     DOI: 10.1111/j.1744-313x.1996.tb00275.x

Source DB:  PubMed          Journal:  Eur J Immunogenet        ISSN: 0960-7420


  5 in total

1.  HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis.

Authors:  P C Stokkers; P H Reitsma; G N Tytgat; S J van Deventer
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

3.  Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease.

Authors:  A Cariappa; B Sands; D Forcione; D Finkelstein; D K Podolsky; S Pillai
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

4.  Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease.

Authors:  O Cohavy; G Harth; M Horwitz; M Eggena; C Landers; C Sutton; S R Targan; J Braun
Journal:  Infect Immun       Date:  1999-12       Impact factor: 3.441

Review 5.  Progress in searching for susceptibility gene for inflammatory bowel disease by positional cloning.

Authors:  Chang-Qing Zheng; Gang-Zheng Hu; Zhao-Shu Zeng; Lian-Jie Lin; Gin-Ge Gu
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.